Difference between revisions of "Aripiprazole-Haloperidol"
From Psychiatrienet
| Line 2: | Line 2: | ||
| from = Aripiprazole | | from = Aripiprazole | ||
| to = Haloperidol | | to = Haloperidol | ||
| − | | stop = {{ | + | | stop = |
| + | * '''Day 1-21:''' {{Cont}} | ||
| + | * '''Day 22:''' {{Stop}} | ||
| start = {{StartStand}} | | start = {{StartStand}} | ||
| + | * '''Day 28:''' Reevaluate dose, if necessary adjust dose | ||
| + | | view = StopAbruptly21StartGradually2.jpg | ||
| info = {{caveQT}} | | info = {{caveQT}} | ||
| − | |||
| − | |||
Revision as of 09:47, 12 August 2009
{{Drugswitch | from = Aripiprazole | to = Haloperidol | stop =
- Day 1-21: Continue drug at usual dose
- Day 22: Stop drug
| start =
- Day 1-4: approx. 25% of target dose
- Day 5-8: approx. 50% of target dose
- Day 9-12: approx. 75% of target dose
- Day 13: target dose
- Day 28: Reevaluate dose, if necessary adjust dose
| view = StopAbruptly21StartGradually2.jpg | info =
- During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
- There is a possibility of QT interval prolongation.[1]
- ↑ Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
